China · Delayed Price · Currency is CNY Guobang Pharma Statistics
Total Valuation
Guobang Pharma has a market cap or net worth of CNY 11.64 billion. The enterprise value is 10.37 billion.
| Market Cap | 11.64B |
| Enterprise Value | 10.37B |
Important Dates
The next estimated earnings date is Wednesday, July 30, 2025.
| Earnings Date | Jul 30, 2025 |
| Ex-Dividend Date | Jun 13, 2025 |
Share Statistics
Guobang Pharma has 558.37 million shares outstanding. The number of shares has increased by 1.07% in one year.
| Current Share Class | 558.37M |
| Shares Outstanding | 558.37M |
| Shares Change (YoY) | +1.07% |
| Shares Change (QoQ) | +0.44% |
| Owned by Insiders (%) | 12.67% |
| Owned by Institutions (%) | 5.32% |
| Float | 192.83M |
Valuation Ratios
The trailing PE ratio is 14.68 and the forward PE ratio is 12.45.
| PE Ratio | 14.68 |
| Forward PE | 12.45 |
| PS Ratio | 1.94 |
| PB Ratio | 1.41 |
| P/TBV Ratio | 1.47 |
| P/FCF Ratio | 115.76 |
| P/OCF Ratio | 26.83 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.97, with an EV/FCF ratio of 103.08.
| EV / Earnings | 12.99 |
| EV / Sales | 1.73 |
| EV / EBITDA | 7.97 |
| EV / EBIT | 12.34 |
| EV / FCF | 103.08 |
Financial Position
The company has a current ratio of 2.51, with a Debt / Equity ratio of 0.13.
| Current Ratio | 2.51 |
| Quick Ratio | 1.57 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | 0.81 |
| Debt / FCF | 10.47 |
| Interest Coverage | 32.98 |
Financial Efficiency
Return on equity (ROE) is 10.04% and return on invested capital (ROIC) is 5.84%.
| Return on Equity (ROE) | 10.04% |
| Return on Assets (ROA) | 4.88% |
| Return on Invested Capital (ROIC) | 5.84% |
| Return on Capital Employed (ROCE) | 9.74% |
| Revenue Per Employee | 1.50M |
| Profits Per Employee | 199,311 |
| Employee Count | 4,003 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 3.13 |
Taxes
In the past 12 months, Guobang Pharma has paid 106.52 million in taxes.
| Income Tax | 106.52M |
| Effective Tax Rate | 11.80% |
Stock Price Statistics
The stock price has increased by +22.01% in the last 52 weeks. The beta is 0.35, so Guobang Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | +22.01% |
| 50-Day Moving Average | 20.10 |
| 200-Day Moving Average | 20.09 |
| Relative Strength Index (RSI) | 60.61 |
| Average Volume (20 Days) | 2,838,864 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Guobang Pharma had revenue of CNY 5.99 billion and earned 797.84 million in profits. Earnings per share was 1.42.
| Revenue | 5.99B |
| Gross Profit | 1.45B |
| Operating Income | 840.13M |
| Pretax Income | 902.77M |
| Net Income | 797.84M |
| EBITDA | 1.30B |
| EBIT | 840.13M |
| Earnings Per Share (EPS) | 1.42 |
Balance Sheet
The company has 2.33 billion in cash and 1.05 billion in debt, giving a net cash position of 1.28 billion or 2.29 per share.
| Cash & Cash Equivalents | 2.33B |
| Total Debt | 1.05B |
| Net Cash | 1.28B |
| Net Cash Per Share | 2.29 |
| Equity (Book Value) | 8.26B |
| Book Value Per Share | 14.59 |
| Working Capital | 3.77B |
Cash Flow
In the last 12 months, operating cash flow was 433.85 million and capital expenditures -333.29 million, giving a free cash flow of 100.57 million.
| Operating Cash Flow | 433.85M |
| Capital Expenditures | -333.29M |
| Free Cash Flow | 100.57M |
| FCF Per Share | 0.18 |
Margins
Gross margin is 24.18%, with operating and profit margins of 14.02% and 13.31%.
| Gross Margin | 24.18% |
| Operating Margin | 14.02% |
| Pretax Margin | 15.07% |
| Profit Margin | 13.31% |
| EBITDA Margin | 21.71% |
| EBIT Margin | 14.02% |
| FCF Margin | 1.68% |
Dividends & Yields
This stock pays an annual dividend of 0.60, which amounts to a dividend yield of 2.88%.
| Dividend Per Share | 0.60 |
| Dividend Yield | 2.88% |
| Dividend Growth (YoY) | 100.92% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 24.09% |
| Buyback Yield | -1.07% |
| Shareholder Yield | 1.81% |
| Earnings Yield | 6.85% |
| FCF Yield | 0.86% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Guobang Pharma has an Altman Z-Score of 3.89 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.89 |
| Piotroski F-Score | 7 |